Journal of Antimicrobial Chemotherapy (2004) 53, ii23-ii28
© 2004 The British Society for Antimicrobial Chemotherapy
Supplement |
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians
1 University of Arizona College of Pharmacy, Tucson, AZ; 2 Merck Research Laboratories, BL 3–4, PO Box 4, West Point, PA 19486, USA
Abstract
Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral ß-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected.
Keywords: carbapenems, metabolism, excretion, distribution, protein binding, renal insufficiency
Footnotes
* Corresponding author. Tel: +1-484-344-3331; Fax: +1-484-344-3404; E-mail: mark_dinubile{at}merck.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, P. Baudry, V. Vashisht, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum {beta}-lactamase-producing Escherichia coli using an in vitro model J. Antimicrob. Chemother., March 1, 2008; 61(3): 643 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. d. Santos, J. R. Nicoli, W. A. Martins, S. C. Coutinho, A. C. M. Apolonio, C. G. Diniz, M. A. R. d. Carvalho, and L. d. M. Farias Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli J. Med. Microbiol., November 1, 2007; 56(11): 1576 - 1579. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DeRyke, M. A. Banevicius, H. W. Fan, and D. P. Nicolau Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1481 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shibayama, Y. Matsushita, K. Kawai, T. Hirota, T. Ikeda, and S. Kuwahara Pharmacokinetics and Disposition of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Animals Antimicrob. Agents Chemother., January 1, 2007; 51(1): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model J. Antimicrob. Chemother., January 1, 2007; 59(1): 144 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Mistry, A. K. Majumdar, S. Swan, D. Sica, A. Fisher, Y. Xu, M. Hesney, L. Xi, J. A. Wagner, and P. J. Deutsch Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J. Clin. Pharmacol., October 1, 2006; 46(10): 1128 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis J. Antimicrob. Chemother., September 1, 2006; 58(3): 632 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1222 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wittau, E. Wagner, V. Kaever, T. Koal, D. Henne-Bruns, and R. Isenmann Intraabdominal tissue concentration of ertapenem J. Antimicrob. Chemother., February 1, 2006; 57(2): 312 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, S. Mushtaq, and M. Warner Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems J. Antimicrob. Chemother., March 1, 2005; 55(3): 306 - 311. [Abstract] [Full Text] [PDF]
|
|